Teaser text

Development of quorum-sensing inhibitors, antimicrobial peptides and mimics, and incorporating them into polymers and biomaterials with the aim of reducing device-related infections.

Body Text

Competitive advantage

  • Portfolio of antimicrobial and antibiofilm agents and scaffolds with novel mechanisms of action
  • Antimicrobial coatings technologies with demonstrated in-vivo efficacy at preventing device-related infections
  • Recognised international experts in the field of antimicrobial discovery and biomaterials
  • Outstanding track record in the area of novel surface strategies for antimicrobial control, with multiple industry-supported and government funding in this area


  • Up to 65% of all hospital-acquired infections are caused by microbial colonisation of surfaces. This is a major health problem that can be prevented by new technologies which will save billions of dollars in healthcare costs and provide substantial economic benefits for industries.

Successful outcomes

  • Completed Phase I/Phase III clinical trials for antimicrobial contact lenses
  • Antimicrobial prototype devices for major biomedical companies including Cochlear

Capabilities and facilities

  • World-class synthetic chemistry facilities including NMR and mass spectrometry, supported by a diverse range of imaging and surface characterisation facilities from the Mark Wainwright Analytical Centre
  • Clinically relevant animal models for device-related infections

Our partners

  • Biosignal Ltd
  • Cochlear Ltd
  • Australian Biotechnologies Pty Ltd
  • Intellectual Ventures (now Xinova)
  • Allegra Orthopaedics